Request Demo
Last update 16 May 2025
Anti-CD19 CAR-T therapy(Wuhan Si'an Medical Technology)
Last update 16 May 2025
Overview
Basic Info
Drug Type CAR-T |
Synonyms- |
Target |
Action modulators |
Mechanism CD19 modulators(B-lymphocyte antigen CD19 modulators) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
6
Clinical Trials associated with Anti-CD19 CAR-T therapy(Wuhan Si'an Medical Technology)NCT05020392
Efficacy and Safety of Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma：a Single-center, Open-label, Pragmatic Clinical Trial
NL-OMON20380
Late Effects and Follow up after pediatric hematological stem cell transplantation and cell therapy (LEEF)
NCT04008251
Treatment of Relapsed or Refractory B-cell Malignancies by Humanized CD19 Chimeric Antigen Receptor (CAR)-Modified T Cells
100 Clinical Results associated with Anti-CD19 CAR-T therapy(Wuhan Si'an Medical Technology)
Login to view more data
100 Translational Medicine associated with Anti-CD19 CAR-T therapy(Wuhan Si'an Medical Technology)
Login to view more data
100 Patents (Medical) associated with Anti-CD19 CAR-T therapy(Wuhan Si'an Medical Technology)
Login to view more data
100 Deals associated with Anti-CD19 CAR-T therapy(Wuhan Si'an Medical Technology)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Burkitt Lymphoma | Phase 3 | China | 14 Sep 2021 | |
| Chronic Lymphocytic Leukemia | Phase 3 | China | 14 Sep 2021 | |
| Diffuse Large B-Cell Lymphoma | Phase 3 | China | 14 Sep 2021 | |
| Follicular Lymphoma | Phase 3 | China | 14 Sep 2021 | |
| Mantle-Cell Lymphoma | Phase 3 | China | 14 Sep 2021 | |
| CD19 Expressing Malignancies | Phase 2 | China | 15 Apr 2016 | |
| CD19 Expressing Malignancies | Phase 2 | China | 15 Apr 2016 | |
| CD19 Expressing Malignancies | Phase 2 | China | 15 Apr 2016 | |
| Marginal Zone B-Cell Lymphoma | Phase 2 | China | 15 Apr 2016 | |
| Marginal Zone B-Cell Lymphoma | Phase 2 | China | 15 Apr 2016 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free